Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review.

J Rheumatol

From the Department of Internal Medicine, Université Caen Normandie, Medical School, CHU de Caen, Caen; Department of Internal Medicine, Tenon Hospital, University Pierre and Marie Curie-Paris 6; Department of Pediatric Immunology, Hematology and Rheumatology, Hôpital Necker, Paris; Department of Internal Medicine, Edouard Herriot Hospital, Lyon; Department of Internal Medicine, Claude Huriez Hospital, University of Lille, Lille; Department of Internal Medicine, CH de Périgueux, Périgueux; Department of Internal Medicine and Clinical Immunology, CHU de Dijon, Dijon; Department of Internal Medicine, CHU de Rennes, Rennes; Department of Internal Medicine and Vascular Diseases, CHU d'Angers, Angers; Department of Rheumatology, CH de Colmar, Colmar, France.

Published: March 2018

Objective: To report efficacy and tolerance of interleukin 1 blockade in adult patients with mevalonate kinase deficiency (MKD).

Methods: We retrospectively collected data on 13 patients with MKD who had received anakinra (n = 10) and canakinumab (n = 7).

Results: Anakinra resulted in complete or partial remission in 3/10 and 5/10 patients, respectively, and no efficacy in 2/10, but a switch to canakinumab led to partial remission. Canakinumab resulted in complete or partial remission in 3/7 and 4/7 patients, respectively.

Conclusion: These data support frequent partial responses, showing a better response with canakinumab. The genotype and therapeutic outcomes correlation should help in the personalization of treatment.

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.170684DOI Listing

Publication Analysis

Top Keywords

partial remission
12
interleukin blockade
8
mevalonate kinase
8
kinase deficiency
8
adult patients
8
complete partial
8
patients
5
efficacy continuous
4
continuous interleukin
4
blockade mevalonate
4

Similar Publications

Pemphigus vulgaris is a chronic autoimmune blistering disease with significant morbidity. Rituximab, approved as its first-line treatment, effectively induces remission. However, few studies have analysed the prognostic factors for improved rituximab outcomes.

View Article and Find Full Text PDF

Introduction: Head and neck squamous cell carcinoma (HNSCC), a highly heterogeneous malignancy is often associated with unfavorable prognosis. Due to its unique anatomical position and the absence of effective early inspection methods, surgical intervention alone is frequently inadequate for achieving complete remission. Therefore, the identification of reliable biomarker is crucial to enhance the accuracy of screening and treatment strategies for HNSCC.

View Article and Find Full Text PDF

Purpose: This study aimed to investigate the usefulness of ultrasound-guided core-needle biopsy (US-CNB) for diagnosing type 1 AIP and evaluate the radiological outcomes following steroid therapy.

Materials And Methods: From January 2017 to June 2023, patients with pathology results containing "lymphoplasmacytic infiltration" and "fibrosis" were enrolled. The detection rate of level 1 histology by International Consensus Diagnostic Criteria (ICDC) and the contribution of US-CNB were assessed.

View Article and Find Full Text PDF
Article Synopsis
  • This study tested rituximab (RTX) on patients with primary membranous nephropathy (PMN) who were dependent on calmodulin inhibitors (CNIs) and not fully in remission.
  • Among 36 patients, those who were drug-dependent showed a significant reduction in proteinuria and improved remission rates after 12 months of RTX therapy, with complete remission increasing from 10% to 70%.
  • The results indicated that RTX not only helped patients overcome CNI dependency but also led to significant immunological improvements while minimizing the risks of adverse effects.
View Article and Find Full Text PDF

[Clinical Analysis of 25 Cases of Acquired Hemophilia A in a Single Center].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

December 2024

Department of Hematology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang 050000, Hebei Province, China.

Objective: To explore the diagnosis and treatment of acquired hemophilia A (AHA) based on the analysis of clinical data.

Methods: A retrospective analysis was conducted on the clinical manifestations, laboratory characteristics, treatment, and outcomes of 25 patients diagnosed with AHA who were admitted to the Second Hospital of Hebei Medical University.

Results: Among all patients, 11 cases had secondary factors, including 5 cases of autoimmune diseases, 3 cases of pregnancy-related disease, 1 case of pemphigoid, 1 case of Graves' disease, and 1 case of monoclonal gammaglobulinemia of unknown significance (MGUS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!